DOT1L and acute myeloid leukemia: They identified numerous targets, including Bromodomain-containing Protein 4 (BRD4), Histone Methyltransferase DOT1L (DOT1L), and Multiple endocrine neoplasia type 1 (MEN1) for Acute Myeloid Leukemia (AML) (Tzelepis et al., 2016).